Does Presbyterian Healthcare Services Cover Vyvanse?

How Presbyterian Healthcare Services Classifies Vyvanse on Its Formulary

Presbyterian Healthcare Services, the largest health system and insurer based in New Mexico, maintains a tiered formulary that determines member cost-sharing for prescription drugs. Vyvanse (lisdexamfetamine dimesylate) appears on most Presbyterian formularies as a Tier 3 preferred brand or Tier 4 non-preferred brand medication, depending on the specific plan year and product line.

The distinction matters financially. Tier 3 medications on Presbyterian commercial plans generally carry copays between $30 and $60 per fill, while Tier 4 non-preferred brands can cost $60 to $100 or more 1. Presbyterian updates its formulary quarterly, so tier placement can shift mid-year. Members should verify current placement through the Presbyterian online formulary search tool or by calling the pharmacy benefits number on their member ID card.

Lisdexamfetamine received FDA approval in 2007 for ADHD in children aged 6 and older, with subsequent approvals for adult ADHD (2008) and moderate-to-severe binge eating disorder in adults (2015) 2. Because it is a prodrug that requires enzymatic conversion to active d-amphetamine in the body, it carries a lower abuse potential profile compared with immediate-release amphetamine formulations, though it remains a DEA Schedule II controlled substance.

Prior Authorization Requirements for Vyvanse

Presbyterian requires prior authorization for Vyvanse on nearly all plan types. This is standard practice. A 2023 analysis found that 91% of commercial insurers require some form of utilization management for brand-name ADHD stimulants 3.

To obtain prior authorization through Presbyterian, prescribers typically need to document:

• A confirmed diagnosis of ADHD (using DSM-5 criteria) or binge eating disorder
• Patient age (Vyvanse is FDA-approved for ADHD in ages 6+, and for BED in adults 18+)
• Trial and failure of, or clinical contraindication to, at least one preferred formulary stimulant (often generic mixed amphetamine salts or generic methylphenidate)
• That the requested dose falls within FDA-approved ranges (20 mg to 70 mg daily for ADHD; 50 mg to 70 mg daily for BED)

Step therapy is the most common barrier. Presbyterian, like many plans, prefers that members try less expensive alternatives first. Generic mixed amphetamine salts (the generic equivalent of Adderall) and generic methylphenidate ER typically sit on Tier 1 or Tier 2 of Presbyterian formularies, costing $5 to $25 per fill. A prescriber who documents clinical reasons why these alternatives are inappropriate (side effects, treatment failure, or specific pharmacokinetic needs) can request a formulary exception.

The prior authorization process at Presbyterian generally takes 48 to 72 hours for standard requests. Urgent requests, where the prescriber attests that the standard timeline could seriously jeopardize the patient's health, receive a decision within 24 hours.

Coverage Differences Across Presbyterian Plan Types

Presbyterian operates several distinct product lines in New Mexico, and Vyvanse coverage varies across them. Understanding which plan you carry determines your actual out-of-pocket costs and access pathway.

Presbyterian Commercial (HMO and PPO): These employer-sponsored and individual market plans place Vyvanse on the brand formulary tier. Most commercial plans require prior authorization with step therapy. Copays for brand-tier drugs on Presbyterian commercial plans typically range from $35 to $75, though high-deductible health plans (HDHPs) may require members to pay full price until meeting the deductible. A 30-day supply of brand Vyvanse without insurance averages $380 to $430 at New Mexico pharmacies 4.

Presbyterian Centennial Care (Medicaid): Presbyterian administers Centennial Care, New Mexico's Medicaid managed care program, for a large portion of the state's Medicaid population. Under Centennial Care, Vyvanse coverage follows the New Mexico Medicaid preferred drug list. Prior authorization is typically required, and the medication may carry a nominal copay of $0 to $3 for eligible members. Medicaid plans must cover all FDA-approved medications with a federal rebate agreement, but they can impose prior authorization and preferred alternatives.

Presbyterian Medicare Advantage: Medicare Part D formularies have their own tier structure governed by CMS guidelines. Vyvanse, when covered, usually falls on Tier 4 (non-preferred brand) of Presbyterian Medicare Advantage Part D plans. The coverage gap ("donut hole") phase may significantly increase out-of-pocket costs. Since 2025, the Inflation Reduction Act caps Medicare Part D out-of-pocket spending at $2,000 annually, which benefits members taking expensive brand medications 5.

The Generic Lisdexamfetamine Option

The FDA approved the first generic versions of Vyvanse (lisdexamfetamine dimesylate capsules) in August 2023, after Takeda's patent exclusivity expired 6. Multiple manufacturers now produce generic lisdexamfetamine, which has driven costs down substantially.

Generic lisdexamfetamine on Presbyterian plans generally sits on Tier 2 (preferred generic or preferred brand), with copays ranging from $15 to $40 per fill. Some Presbyterian plans may waive the prior authorization requirement for the generic version, though step therapy through first-line generics (amphetamine salts, methylphenidate) may still apply.

The clinical equivalence is established. Generic lisdexamfetamine must demonstrate bioequivalence to brand Vyvanse within the FDA's 80% to 125% confidence interval for AUC and Cmax, meaning the therapeutic effect is functionally identical. A member currently stable on brand Vyvanse can switch to generic lisdexamfetamine without expecting any change in efficacy or side-effect profile 7.

If your Presbyterian plan has moved brand Vyvanse to a non-preferred tier but covers generic lisdexamfetamine at a lower tier, requesting the generic through your prescriber is the most direct way to reduce costs while maintaining the same medication.

How to Check Your Specific Presbyterian Coverage

Formulary placement, copay amounts, and prior authorization requirements vary by plan, plan year, and employer group. These steps will give you a definitive answer for your specific situation.

Step 1: Log in to myPRES. Presbyterian's member portal (myPRES) provides access to your plan's current formulary, including tier placement and any utilization management requirements for Vyvanse or generic lisdexamfetamine. The drug search function allows you to look up coverage by medication name.

Step 2: Call Pharmacy Benefits. The phone number on the back of your Presbyterian member ID card connects you to pharmacy benefits services. Ask specifically: "Is lisdexamfetamine or Vyvanse on my formulary, what tier is it, and does it require prior authorization?" Request the information in writing if possible.

Step 3: Ask about the preferred alternative list. If prior authorization requires step therapy, ask which specific medications Presbyterian considers preferred alternatives. This allows your prescriber to document trials of those exact drugs when submitting the authorization request.

Step 4: Explore manufacturer assistance. Takeda offers a Vyvanse savings card for commercially insured patients that can reduce copays to as low as $30 per fill, with a maximum annual benefit. This program does not apply to government-funded insurance (Medicaid, Medicare, TRICARE). The savings card can be used alongside Presbyterian commercial insurance to offset brand-tier copays.

What to Do If Presbyterian Denies Vyvanse Coverage

A denial is not the end of the process. Presbyterian, like all health plans, must provide a formal appeals pathway. The denial letter will include specific reasons for the decision and instructions for appeal.

The most effective appeals include documentation from the prescriber explaining why Vyvanse (or generic lisdexamfetamine) is medically necessary for the specific patient. Clinical evidence supporting lisdexamfetamine over alternatives is strongest for patients who have experienced intolerable side effects with other stimulants, who need the prodrug's smoother pharmacokinetic profile, or who have a documented history of stimulant misuse where the abuse-deterrent properties of lisdexamfetamine offer a clinical advantage 8.

A randomized study (N=420) demonstrated that lisdexamfetamine's prodrug mechanism produced significantly lower subjective "drug liking" scores compared to equivalent doses of immediate-release d-amphetamine, supporting its use in patients where abuse potential is a clinical consideration 9.

Presbyterian members can also file an external review through the New Mexico Office of Superintendent of Insurance if they believe the denial was inappropriate. External reviews are conducted by independent physicians not affiliated with Presbyterian.

For Centennial Care (Medicaid) members, denials can be appealed through the New Mexico Human Services Department fair hearing process, which provides an additional layer of review beyond the plan-level appeal.

Vyvanse Dosing and Cost Implications on Presbyterian Plans

Understanding dose-cost relationships can help members and prescribers make cost-effective choices. Vyvanse capsules come in seven strengths: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. A critical cost detail: all strengths of brand Vyvanse carry the same price. A 30-day supply of 10 mg capsules costs the same as 70 mg capsules at the pharmacy level.

This uniform pricing means that "pill splitting" strategies used with some other medications do not apply. Vyvanse capsules should not be split. They can, however, be opened and the powder dissolved in water for patients who cannot swallow capsules, per the FDA-approved labeling.

For Presbyterian members, the copay is the same regardless of Vyvanse dose. The clinical goal should be finding the lowest effective dose, not a dose chosen for cost reasons. The FDA-approved titration schedule for ADHD begins at 30 mg daily, increasing by 10 mg to 20 mg weekly to a maximum of 70 mg daily 2.

For binge eating disorder, the recommended dose is 50 mg to 70 mg daily, with titration starting at 30 mg. A 12-week RCT (N=517) found that lisdexamfetamine 50 mg and 70 mg reduced binge eating days from a baseline of approximately 4.5 per week to 1.5 and 1.0 per week, respectively, versus 2.5 per week with placebo (P<0.001 for both doses vs. placebo) 10.

Presbyterian Coverage for Vyvanse in Pediatric ADHD

ADHD medications represent one of the most commonly prescribed drug classes in pediatric populations. The American Academy of Pediatrics (AAP) 2019 clinical practice guideline recommends FDA-approved medications for ADHD in children aged 6 and older, with stimulants as first-line pharmacotherapy 11.

Presbyterian Centennial Care covers a large share of New Mexico's pediatric population. For children with ADHD on Centennial Care, the prior authorization pathway for Vyvanse typically requires documentation that the child has tried at least one preferred stimulant (usually generic methylphenidate or generic amphetamine salts) without adequate response or with intolerable side effects.

Lisdexamfetamine's once-daily dosing and 12- to 14-hour duration of action make it a common choice for school-age children. A meta-analysis of 133 randomized trials (N=24,177) published in The Lancet Psychiatry found lisdexamfetamine among the most efficacious medications for ADHD in children and adolescents based on teacher-rated symptom improvement 12.

For pediatric patients on Presbyterian plans, generic lisdexamfetamine offers the same clinical benefit at a lower tier. Parents should discuss this option with the prescriber if cost is a barrier.

Comparing Vyvanse to Preferred Presbyterian Alternatives

Presbyterian's step therapy requirement assumes that certain lower-cost alternatives are therapeutically appropriate for most patients before approving Vyvanse. The most common preferred alternatives on Presbyterian formularies include:

Generic mixed amphetamine salts (Adderall generic): Available in immediate-release (twice daily) and extended-release (once daily) formulations. Cost on Presbyterian: typically $5 to $20 per fill. Amphetamine salts ER provides 10 to 12 hours of coverage. The key clinical difference from Vyvanse is the pharmacokinetic profile. Amphetamine salts ER uses a bead-based delivery system, while lisdexamfetamine relies on enzymatic conversion, producing a smoother plasma concentration curve.

Generic methylphenidate ER (Concerta generic, others): The other major stimulant class. OROS methylphenidate (the Concerta delivery system) provides 10 to 12 hours of effect. Presbyterian typically covers this at Tier 1 or Tier 2. A Cochrane review of 38 studies (N=5,111) found no significant difference in efficacy between methylphenidate and amphetamine-class drugs for ADHD symptoms in children and adults, though individual response varies 13.

Atomoxetine (Strattera generic): A non-stimulant SNRI approved for ADHD. Not a controlled substance. Useful for patients with substance use history or anxiety comorbidity. Slower onset (4 to 6 weeks for full effect). Generally Tier 1 or Tier 2 on Presbyterian formularies.

Documenting why these alternatives are clinically inappropriate for a specific patient remains the most reliable path to Vyvanse prior authorization approval.